{"id":"lutetium-177","rwe":[{"pmid":"41712768","year":"2026","title":"Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in (177)Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial.","journal":"JMIR research protocols"},{"pmid":"41701883","year":"2026","title":"Trajectory timelines and treatment efficacy of (177)Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center.","journal":"Canadian Urological Association journal = Journal de l'Association des urologues du Canada"},{"pmid":"41630499","year":"2026","title":"Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.","journal":"The oncologist"},{"pmid":"41620317","year":"2026","title":"Treatment Discontinuation in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Lutetium-177 ((177)Lu)-PSMA-617: A Retrospective Real-World Study.","journal":"Clinical genitourinary cancer"},{"pmid":"41598623","year":"2026","title":"Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium ((177)Lu)Vipivotide Tetraxetan, and Abiraterone.","journal":"Journal of clinical medicine"}],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT05701007"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"Lutetium-177 is a radioactive therapeutic agent that delivers targeted cancer-killing radiation directly to tumor cells. It works by binding to specific proteins on cancer cells and emitting radiation that destroys them from within. This approach allows for effective treatment while minimizing exposure to healthy tissue.","brandName":"Lutetium-177","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"mCRPC","explanation":"Lutetium-177 is a radioactive isotope used in targeted cancer therapy. It works by being attached to molecules that seek out and bind to specific proteins found on the surface of cancer cells. Once these molecules find their targets, they deliver the Lutetium-177 directly to the tumor, where the radioactive element can do its work.\n\nOnce bound to cancer cells, Lutetium-177 releases radiation in the form of particles that cause damage to the cell's DNA and other critical structures. This radiation is strong enough to kill cancer cells but works locally—meaning the damaging radiation mainly affects the cancer cells it's attached to rather than spreading throughout the body.\n\nThis targeted approach offers an advantage over traditional chemotherapy: it can attack cancer cells while sparing many healthy cells that don't have the target protein. The radiation dose is concentrated where it's needed most, potentially making treatment more effective and causing fewer side effects compared to treatments that attack all cells indiscriminately.","oneSentence":"mCRPC","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"lutetium-177","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Metastatic Castration Sensitive Prostate Cancer (mCSPC)","phase":"preclinical","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05701007","phase":"N/A","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finlan","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":1083,"indication":"Metastatic Castration Sensitive Prostate Cancer (mCSPC)","completionDate":"2024-04","primaryEndpoint":"Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL4297545","pubchemSID":"113446114"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}